In the Phase II study (NCT01941927), the combination of trametinib and GSK2141795 does not have significant clinical activity in NRAS‐mutant melanoma, no objective responses were observed, and the mPFS and mOS were only 2.3 months (95% CI, 2.1–2.5 months) and 4.0 months (95% CI, 0.9–7.0 months) [248]. Here, NRAS is linked to melanoma.